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Abstract
Aim: To compare the impact of two long-term weight-maintenance diets, a high pro-
tein (HP) and low glycaemic index (GI) diet versus a moderate protein (MP) and mod-
erate GI diet, combined with either high intensity (HI) or moderate intensity physical
activity (PA), on the incidence of type 2 diabetes (T2D) after rapid weight loss.
Materials and Methods: A 3-year multicentre randomized trial in eight countries
using a 2 x 2 diet-by-PA factorial design was conducted. Eight-week weight reduction
was followed by a 3-year randomized weight-maintenance phase. In total, 2326
adults (age 25-70 years, body mass index ≥ 25 kg/m2) with prediabetes were
enrolled. The primary endpoint was 3-year incidence of T2D analysed by diet treat-
ment. Secondary outcomes included glucose, insulin, HbA1c and body weight.
Results: The total number of T2D cases was 62 and the cumulative incidence rate
was 3.1%, with no significant differences between the two diets, PA or their combi-
nation. T2D incidence was similar across intervention centres, irrespective of attri-
tion. Significantly fewer participants achieved normoglycaemia in the HP compared
with the MP group (P < .0001). At 3 years, normoglycaemia was lowest in HP-HI
(11.9%) compared with the other three groups (20.0%-21.0%, P < .05). There were no
group differences in body weight change (−11% after 8-week weight reduction; −5%
after 3-year weight maintenance) or in other secondary outcomes.
Conclusions: Three-year incidence of T2D was much lower than predicted and did
not differ between diets, PA or their combination. Maintaining the target intakes of
protein and GI over 3 years was difficult, but the overall protocol combining weight
loss, healthy eating and PA was successful in markedly reducing the risk of T2D. This
is an important clinically relevant outcome.
K E YWORD S
behaviour change, carbohydrate, dietary intervention, exercise intervention, glycaemic control,
obesity
1 | INTRODUCTION
The rate of type 2 diabetes (T2D) continues to increase on a global
level with serious consequences for the individual and the commu-
nity.1 Weight gain resulting in overweight and obesity is the main risk
factor for developing T2D, whereas weight loss appears to be a key
determinant of prevention of T2D in predisposed individuals.2,3
Weight maintenance is a critical component of solving both the obe-
sity and T2D epidemic and tools to effectively implement weight
maintenance after significant weight loss are therefore needed. The
DiRECT study showed that after a 12-month intensive weight
management programme in participants with T2D, the remission rate
was highest in participants who achieved the greatest weight loss
(46% in the intervention group compared with only 4% in the control
group).4 After 24 months, remission was still sustained in 36% versus
3% in the intervention versus control group.5
Previous diabetes prevention studies have found that adherence to
a healthy lifestyle (decreased energy intake, high fibre, high carbohy-
drate diets, increased physical activity [PA]) reduced the incidence of
T2D by 28%-58% in predisposed individuals compared with routine
care.6–9 The multicentre Diet, Obesity and Genes (DiOGenes) trial
found that in overweight, healthy individuals a combined ad libitum high
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protein (HP), moderate carbohydrate, low glycaemic index (GI) diet was
superior to four other diets of varying macronutrient and GI composi-
tion in preventing 6-month weight regain after an initial 8-week, low
energy diet (LED).10 A recent meta-analysis of prospective cohort stud-
ies found that diets with lower GI and glycaemic load (GL) were associ-
ated with a reduced risk ratio for T2D.11 Also, a Mediterranean-based
dietary pattern and a high carbohydrate quality index (in the PREDI-
MED trials) were proven to be beneficial concerning adiposity and risk
factors for T2D and cardiovascular disease.12,13
Despite the shown effect on weight maintenance after weight
loss, the combined effect of an HP, low GI diet for the prevention of
T2D has not yet been investigated. The main objective of the PRE-
VIEW intervention study (PREVention of diabetes through lifestyle
intervention and population studies In Europe and around the
World)14 was, therefore, to determine whether an ad libitum HP, low
GI diet was superior to a conventional moderate protein, moderate GI
diet for weight-loss maintenance and thereby for prevention of T2D
in adults with prediabetes. The second aim was to determine whether
high intensity PA had additional positive effects on outcomes com-
pared with moderate intensity PA. In order to study the effect on
weight maintenance per se, an initial 8-week weight-loss phase using
an LED was conducted adopting a similar design as the DiOGenes
study.10
2 | METHODS
PREVIEW was a multicentre randomized trial including adults and chil-
dren. The details of the study protocols have been described previ-
ously14,15 (clinicaltrials.gov NCT01777893). This paper concerns the
adult participants.
PREVIEW for adults was conducted at eight intervention centres
in eight countries: University of Copenhagen (Denmark), University of
Helsinki (Finland), University of Maastricht (the Netherlands), Univer-
sity of Nottingham (UK), University of Navarra (Spain), Medical Uni-
versity of Sofia (Bulgaria), University of Sydney (Australia) and
University of Auckland (New Zealand). The study protocol and amend-
ments were reviewed and approved by the local Human Ethics Com-
mittee at each of the eight intervention centres. The work of
PREVIEW was carried out in full compliance with the relevant require-
ments of the latest version of the Declaration of Helsinki (59th WMA
General Assembly, Seoul, Korea, October 2008) and The International
Conference on Harmonisation for Good Clinical Practice, to the
extent possible and relevant. All participants provided written
informed consent prior any screening procedures. All information
obtained during the trial was handled according to the local regula-
tions and the European Directive 95/46/CE (directive on protection
of individuals with regard to the processing of personal data and on
the free movement of such data).
The 3-year randomized intervention trial consisted of an 8-week
weight-loss phase followed by a 148-week weight-maintenance
phase. The intervention had a 2 x 2 factorial design with two diets
and two PA programmes.
2.1 | Participants
From June 2013 to April 2015, 2326 men and women with prediabe-
tes (age 25-70 years, body mass index [BMI] ≥ 25 kg/m2) were
enrolled. The last participant visit was in March 2018. Prescreening
was undertaken using the Finnish Diabetes Risk Score,16 specific
inclusion and exclusion criteria,14 and prediabetes according to the
recommended criteria of the American Diabetes Association
(ADA).17 A total of seven clinical investigation days (CIDs) were per-
formed for each participant in the morning fasted state (at baseline,
8, 26, 52, 78, 104 and 156 weeks), including anthropometry, blood
sampling and completion of questionnaires. Furthermore, at base-
line, 26, 52, 104 and 156 weeks, 4-day dietary records, 7-day accel-
erometer data and 24-hour urine samples were collected.
Participants also attended 17 group counselling visits (8-10 partici-
pants) with trained instructors to support the changes in habitual
lifestyles.
2.2 | Interventions
The Cambridge Weight Plan (Northants, UK) was used for the
weight-loss phase.18 Participants who achieved a loss of initial body
weight of 8% or higher could continue in the study. The intervention
diets targeted different macronutrient compositions: HP 25 energy-
% (E%) protein, 30 E% fat, 45 E% carbohydrates, low GI (<50); and
moderate protein (MP) 15 E% protein, 30 E% fat, 55 E% carbohy-
drates, moderate GI (>56).14 Both intervention diets emphasized
healthy food choices. The PA groups were: high intensity (HI) PA for
75 minutes per week; moderate intensity (MI) PA for 150 minutes
per week as recommended.19 More specifically, the HI group partici-
pated in 75 minutes of PA per week at six or more metabolic equiva-
lents of task (METs) (450 MET minutes per week) and the MI group
150 minutes at 3-5.9 METs (450 MET minutes per week). Both PA
groups were therefore guided to expend the same amount of energy
during PA.
The counselling visits (8-12 participants) consisted of specific
behavioural modification techniques designed to educate about and
support adoption of the new diet and PA strategies (PREMIT).20 The
frequency of the visits decreased during weight maintenance. An
instructors' network ensured consistency between centres.
Before trial start, all staff were trained in the procedures at joint
training seminars and via standard operating procedures (SOPs).
Instruction material for lifestyle changes, measures and questionnaires
were also developed for the participants.
2.3 | Primary outcome
The primary endpoint was incidence of T2D according to diet using
an oral glucose tolerance test (OGTT) with 75 g glucose. T2D was
diagnosed based on the World Health Organization criteria21 of either
(a) OGTT with fasting plasma glucose of more than 7.0 mmol/L and/or
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2-hour postprandial plasma glucose of 11.1 mmol/L or higher, or
(b) T2D diagnosed by a medical doctor between the CIDs using ran-
dom plasma glucose of 11.1 mmol/L or higher in the presence of
symptoms of diabetes, an OGTT or HbA1c.
2.4 | Secondary outcomes
Secondary endpoints included incidence of T2D according to PA and the
four combinations, changes in fasting resting glucose, 2-hour glucose,
proportion of participants with normoglycaemia, HbA1c, insulin, C-pep-
tide, homeostatic model assessment of insulin resistance (HOMA-IR),22
Matsuda Index (subgroup, n = 328),23 body weight, BMI, fat mass, fat-
free mass, waist, hip and thigh circumference, and proportion of partici-
pants maintaining ≥0%, ≥5% or ≥10% weight loss after 156 weeks.
All blood samples were drawn from the antecubital vein, stored at
−80C and subsequently analysed at the National Institute for Health
and Welfare, Helsinki (T077, accredited by the Finnish Accreditation
Service, fulfilling the requirements of standard SFS-EN ISO/IEC
17025:2005). Laboratory measurements were performed on an Archi-
tect ci8200 integrated system (Abbott Laboratories, Abbott Park, IL,
USA). Insulin for Matsuda Index was analysed by an immuno-
chemiluminescent method on a Siemens Immulite 2000 (Siemens
Healthcare, Diagnostics Products, Gwynedd, UK). Measurements of
body weight, body composition, height, waist, hip and thigh circumfer-
ence, and blood pressure, were described previously.18
Reported dietary intake was analysed from 4-day weighed dietary
records using national food composition software. Dietary compliance
assessment by biomarkers was undertaken for protein intake (nitrogen
or urea, 24-hour urine samples) using the formula: 24-hour urinary
urea (mmol/day) x 0.22 + 12.5 g protein per day, and conversion fac-
tor urea x 0.4664 = nitrogen.24,25 Nitrogen or urea were analysed
locally at each intervention centre. Urine collection was assured by a
SOP as well as instruction material and tools for the participants. A
urine collection of less than 0.5 L/day was regarded as incomplete.
For assessment of PA, participants wore an ActiSleep+ (ActiGraph
LLC, Pensacola, FL, USA) accelerometer as previously described.14,26
In brief, the accelerometer was attached to an elastic waist belt worn
over the right mid-axillary line 24 hours a day for 7 consecutive days
before each CID, only removing it for water-based activities. After the
removal of nocturnal sleep episodes, participants were included in the
analyses if they wore the monitor for 10 hours or more on 4 or more
days including 1 weekend day. Mean activity counts during valid wear
time (counts per minute [CPM]) were used as an indicator of total PA
volume.27 Data were analysed centrally at Swansea University (UK).
CPM was used to estimate PA.
Adverse events (AEs) were recorded at each CID.
2.5 | Sample size
Sample size estimation of expected T2D incidence was based on the
two diet intervention groups (HP and MP), hypothesizing that a risk
reduction of 25.0% in MP would reduce T2D incidence to 15.8%. The
estimated 25.0% risk reduction was based on outcomes from publi-
shed diabetes prevention trials7,8 and completer analyses. We further
hypothesized that HP would achieve an overall 50.0% diabetes risk
reduction from a baseline risk of 21.0% to a 3-year risk of 10.5%. A
conservative estimate of sample size to detect this difference (15.8%
vs. 10.5%) was 649 per group or 1298 participants in total (two-sided
comparison, power = 80%, alpha = 0.05). We estimated an 30% drop-
out rate (similar to DiOGenes10). Thus, 1854 subjects should start the
weight-maintenance phase. However, to allow for drop-out after
inclusion and for participants not losing ≥8% weight (estimate = 25%),
a total of 2472 participants should be recruited. A secondary power
calculation for HbA1c (using 3-year results from the Diabetes Preven-
tion Study)8 anticipated a difference between the two diet groups of
0.2% points (SD = 0.6% points). Using an 80% power and alpha of
0.05, the estimated sample size for each group was 142. Allowing for
30% drop-out, the sample size required was 205 per group.
2.6 | Randomization and masking
Participants were randomly assigned to one of the four intervention
groups, separately at each centre, stratified by age (25-45, 46-54 and
55-70 years) and gender (men, women) by sequentially assigning par-
ticipants within each stratum to the interventions.28 The allocation
order was concealed from staff and not disclosed to participants until
the group meeting (week 8). Staff and study participants were not
blinded because of the nature of the intervention. However, all staff
involved in data handling and statistical analyses were blinded to the
randomization until analyses were concluded.
2.7 | Statistical analyses
Data are shown as mean ± SEM (± SD for baseline characteristics)
unless otherwise stated. Three-year incidence of T2D was compared
between diets and PA groups by a semi-parametric Cox proportional
hazards regression model, including adjustments for age, BMI, gender,
ethnicity, intervention centre, fasting glucose and 2-hour glucose.
Comparison of diets was adjusted for PA and vice versa. The propor-
tional hazards model assumption was evaluated by means of residual
plots based on Schoenfeld residuals as well as by means of the global
Schoenfeld lack of fit test.
A post hoc analysis compared T2D incidence in intervention cen-
tres with higher (≥30%) versus lower (<30%) attrition rates.
Changes in continuous secondary outcomes from 8 to 156 weeks
were analysed using an analysis of covariance (ANCOVA) linear mixed
model, including three-way interaction between diet, PA and time. The
models were adjusted for baseline values (0 weeks), age and gender
(fixed effects), and participant ID and intervention centre (random
effects). For significant main effects and interactions, pairwise compari-
sons were reported. ANCOVA was used to investigate associations
between outcomes. The binary outcome normoglycaemia (yes/no) was
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analysed using a logistic mixed effects model including the same fixed
and random effects as the linear mixed models. A post hoc analysis was
conducted for weight change after 3 years in participants with a pro-
tein intake of <0.8 and ≥0.8 g/kg per day (biomarker analyses).
Available-case analyses were carried out assuming that missing
data occurred at random. Sensitivity analysis was also conducted
using the intention-to-treat population, defined as all individuals
entering the weight-loss phase. Imputation was conducted using base-
line observation carried forward.
The statistical environment R was used for all analyses (version
3.6.3).29 P less than .05 was considered statistically significant.
3 | RESULTS
In total, 2326 individuals were enrolled and randomized into the trial
(Figure 1; Figure S1). Baseline characteristics were similar in the four
intervention groups (Table 1). Women represented 68% of
participants. When 1857 participants had met the criteria for the
weight-maintenance phase (79.8% of all those enrolled), the statistical
power for this timepoint had been reached and recruitment was con-
sequently stopped. Between randomization and baseline, 102 individ-
uals withdrew consent, mainly for personal reasons. One individual
withdrew consent during the study and requested that all data be
deleted. Therefore, 2223 individuals were included in the analyses.
Overall, 1381 participants completed year 1 (74% of those eligible for
the weight-maintenance phase), 1093 year 2 (59%) and 962 year
3 (52%), corresponding to 74% of the goal for completers (n = 1298).
Attrition rate during the 3 years was similar in the four groups.
3.1 | Primary outcome
T2D incidence was 3.0% for the HP and 3.2% for the MP diet
(ns) (Figure 2, top). Sixty-two participants developed T2D, 30 on HP
and 32 on MP (adjusted hazard ratio [aHR] for MP vs. HP: 1.22 (95%
F IGURE 1 Participant flow during the trial (see Figure S1 for all details of exclusion). HP-MI: high protein, moderate intensity. HP-HI: high
protein, high intensity. MP-MI: moderate protein, moderate intensity. MP-HI: moderate protein, high intensity. *n=2224 attended this visit, but 1
individual requested all data to be deleted and therefore, n= 2223
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confidence interval: 0.73 to 2.05), P = .45; Figure 2, top). Incidence in
both groups was less than one third of predicted incidence
(HP = 10.5%, MP = 15.8%). Post hoc analyses showed that T2D inci-
dence was 3.0% in intervention centres with higher (≥30%) and 3.4%
in centres with lower (<30%) attrition rates (P = .24).
3.2 | Secondary outcomes
T2D incidence was 2.5% (n = 27) for MI and 3.5% (n = 35) for HI PA.
Adjusted HR was 1.35 (0.80-2.27) for HI versus MI (P = .27). Incidence of
T2D was 11 in HP-MI, 19 in HP-HI, 16 in MP-MI and 16 in MP-HI. Rela-
tive to HP-HI, the aHR for MP-MI was 0.92 (0.46-1.83, P = .81), for MP-
HI 1.10 (0.56-2.17, P = .79) and for HP-MI 0.65 (0.30-1.40, P = .27).
After the LED, 40.2% of those achieving ≥8% weight loss no lon-
ger had prediabetes according to ADA criteria (based on fasting glu-
cose; Figure 2). During the weight-maintenance phase, a significant
effect of diet group was observed, with fewer participants having nor-
moglycaemia in HP than MP (P < .0001). A significant main effect of
the four groups was also observed (P = .0003), with lower numbers in
HP-HI compared with MP-HI (P = .006) and MP-MI (P = .0005), but
not HP-MI (P = .08) (Figure 2). After 3 years, 18.2% of participants
(175 of 962) had normoglycaemia, but significantly fewer in HP-HI
(11.9%) than in HP-MI (20.0%, P = .02), MP-HI (21.0%, P = .0096) and
MP-MI (20.0%, P = .02; Figure 2).
Fasting glucose showed a significant diet*PA interaction
(P = .046; Figure 2), but post hoc pairwise comparisons only showed a
tendency (HP-HI vs. MP-HI, P = .06). Two-hour glucose, fasting insulin
and C-peptide tended to differ (diet*PA*time interaction, P = .05-.1),
but not HOMA-IR, HbA1c (Table 2) or Matsuda Index (Table S1). Body
weight decreased by 11% during the LED phase (P < .0001) and
3-year weight loss averaged 4.6-4.9 kg (n = 962) or 5% of initial
body weight (completers, ns between groups). Imputation or sensitiv-
ity analyses did not change this (Figure S3). At 3 years, 47% of com-
pleters still had a body weight loss of ≥5% (Table S2). Time effect was
significant for all outcomes (P < .0001), and 2 hour-glucose, fasting
insulin and HOMA-IR remained significantly lower after 3 years com-
pared with baseline (P < .05; Table 2). Three-year changes in fasting
glucose, 2-hour glucose, insulin, HbA1c, waist and hip circumference
were significantly correlated with changes in body weight (P < .001).
TABLE 1 Baseline characteristics of the participants in the four intervention groups
HP-MI HP-HI MP-MI MP-HI
No. (women: Men) 555a (371: 184) 556 (379: 177) 559 (379: 180) 553 (374: 179)
Age, years 51.6 ± 11.5 51.8 ± 11.7 51.4 ± 11.2 51.4 ± 11.8
Weight, kg 99.3 ± 20.8 100.6 ± 21.1 101.6 ± 22.6 98.7 ± 20.9
Height, m 1.68 ± 0.09 1.68 ± 0.09 1.68 ± 0.09 1.68 ± 0.10
BMI, kg/m2 35.1 ± 6.5 35.7 ± 6.7 35.7 ± 6.6 35.0 ± 6.4139
HOMA-IRb 3.8 ± 2.5 3.9 ± 2.6 3.7 ± 2.4 3.7 ± 2.2
Fasting glucose, mmol/L 6.2 ± 0.8 6.2 ± 0.7 6.2 ± 0.7 6.2 ± 0.8
2-hour glucose, mmol/L 7.8 ± 2.3 7.7 ± 2.3 7.5 ± 2.2 7.7 ± 2.1
HbA1c, mmol/Mol 36.6 ± 3.8 36.8 ± 3.9 36.7 ± 4.5 36.8 ± 4.0
Insulin, pmol/L 13.6 ± 7.9 14.0 ± 8.7 13.3 ± 7.9 13.1 ± 7.2
C-peptide, pmol/L 918 ± 353 940 ± 359 916 ± 337 921 ± 348
ALT, U/L 27.9 ± 16.3 27.1 ± 16.1 29.3 ± 17.7 27.3 ± 15.1
AST, U/L 27.4 ± 9.6 27.4 ± 11.1 28.5 ± 11.4 27.5 ± 10.5
Waist circumference, cm 109.7 ± 14.4 111.2 ± 14.5 111.1 ± 15.4 109.7 ± 14.5
Hip circumference, cm 117.8 ± 13.7 119.0 ± 14.0 119.3 ± 13.9 117.9 ± 13.8
Thigh circumference, cm 60.2 ± 7.6 60.4 ± 7.3 60.7 ± 7.4 60.1 ± 7.0
Fat-free mass, kg 56.4 ± 11.7 56.6 ± 12.0 57.2 ± 12.7 55.9 ± 11.6
Fat mass, kg 42.4 ± 13.5 43.3 ± 13.5 44.1 ± 14.3 42.3 ± 13.4
Fat mass, % 43.0 ± 7.5 43.5 ± 7.6 43.6 ± 7.5 43.1 ± 7.9
SBP, mmHg 128.5 ± 15.6 129.7 ± 16.2 128.7 ± 16.3 129.3 ± 15.5
DBP, mmHg 78.2 ± 11.0 77.6 ± 11.2 78.4 ± 11.5 78.3 ± 10.7
Heart rate, bpm 71.2 ± 10.4 71.3 ± 11.1 70.8 ± 10.4 71.7 ± 10.4
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; HOMA-IR, homeo-
stasis model of assessment insulin resistance; HP-HI, high protein diet, high intensity physical activity; HP-MI, high protein diet, moderate intensity physical
activity; MP-HI, moderate protein diet, high intensity physical activity; MP-MI, moderate protein diet, moderate intensity physical activity; SBP, systolic
blood pressure; SD, standard deviation. Data are shown as means ± SD.
aThis number is one less than previously reported (14) as one participant withdrew consent during the intervention and asked to have all data removed.
bThe formula to calculate the HOMA-IR was: fasting insulin (mU/L) x fasting glucose (mmol/L) / 22.5.22
RABEN ET AL. 329
Recorded dietary intake was similar at baseline (Table 3). During
weight maintenance, significantly lower GI, carbohydrate intake and
GL, and significantly higher protein, fat and energy intake, were
observed in HP compared with MP. Compliance by biomarker ana-
lyses showed higher protein intake in HP than MP at 26 and 52 weeks,
but not at 104 or 156 weeks (interaction diet*time, P < .0001). Still,
mean protein intake in MP appeared to remain above 0.8 g/kg daily
from week 26 to 156 (Figure S2, top). A post hoc analysis showed that
participants consuming ≥0.8 g/kg protein daily (n = 639) regained 1.5%
points less weight than participants consuming less than 0.8 g/kg
(n = 261) during weight maintenance (P = .0054, data not shown). Die-
tary intake in the four intervention groups is given in Table S3. Overall,
significant effects were only related to diet and time.
Regarding PA, there were no significant differences in total CPM
(Figure S2, bottom), moderate-to-high PA, high PA or sedentary time
(data not shown).
A significant positive association was found between % atten-
dance at group counselling visits and % weight-loss maintenance
(r = 0.17, P < .0001).
The overall numbers of serious AEs (178 in total) were similar by
diet (P = .27) and PA (P = .91) groups (Table S4).
Participants completing the 3-year intervention were slightly
older, had lower BMI and an overall healthier metabolic profile at
baseline compared with those who withdrew (P < .0001; Table S5).
4 | DISCUSSION
To our knowledge, PREVIEW is the first study to compare 3-year T2D
incidence on an ad libitum HP and low GI (lower GL) versus a MP and
moderate GI (higher GL) weight-maintenance diet in adults with
F IGURE 2 Top: T2D incidence per diet group. Estimated
probability of remaining free of diabetes (Kaplan–Meier plot). HP:
high protein, low GI diet. MP: moderate protein, moderate GI diet. HR
for MP versus HP: 1.22 (95% confidence interval: 0.73-2.05, P = .45).
Normoglycaemia: percentage of participants with normoglycaemia
based on fasting (only week 8) or fasting and 2-hour glucose values by
oral glucose tolerance test. Normoglycaemia (binary outcome: yes/no)
was analysed using a logistic mixed effects model including fixed
effects (outcome at 8 weeks, age, gender, PA or diet intervention) and
participant ID and intervention centres (random effects). P-values:
diet effect: .000074 (fewer participants with normoglycaemia in HP
than MP); PA effect: .09; time effect <.00001; combined (4) groups
effect: .00028 (lower numbers in HP-HI compared with MP-HI,
P = .006 and MP-MI, P = .0005, but not HP-MI, P = .08). Δ fasting
glucose: change in fasting glucose from week 0 presented as means ±
SEM. ANCOVA linear mixed model analysis including three-way
interaction between diet, PA and time. Model was adjusted for
baseline values (0 weeks), age and gender (fixed effects), and
participant ID and intervention centre (random effects). P-values: diet
x PA x time effect: .33; diet x PA effect: .046 (post hoc pairwise
analyses: ns); diet effect: .12; PA effect: .59; time effect: <.00001. Δ
body weight: change in body weight from week 0 presented as means
± SEM. ANCOVA linear mixed model analysis including three-way
interaction between diet, PA and time adjusted for baseline values
(0 weeks), age and gender (fixed effects), and participant ID and
intervention centre (random effects). Time effect: P < .00001. No
other significant effects. HP-MI: high protein, moderate intensity
PA. HP-HI: high protein, high intensity PA. MP-MI: moderate protein,
moderate intensity PA. MP-HI: moderate protein, high intensity PA.
N = week 0: 2223; week 8: 2022; week 26: 1627; week 52: 1381;
week 78: 1243; week 104: 1093; week 156: 962
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overweight and prediabetes. The 3-year incidence of T2D was very
low (3.1%) and did not differ between the two diets or the four diet
and PA combinations. However, fewer participants achieved nor-
moglycaemia in HP than in MP during the weight-maintenance phase.
The incidence of T2D was not different between groups, but was
substantially lower than predicted from previous diabetes prevention
studies (10.5%-15.8%).7,8 This may be because of the large and fast
initial weight loss, which was still partially present after 3 years. Other
possible reasons for the low incidence of T2D include selection bias in
the recruitment process, increasing attrition, higher cases among the
drop-outs, or actually a true null effect.
For the recruitment process, we aimed to use the best possible
methods, that is, the Finnish Diabetes Risk Score (FINDRISK) for pres-
creening and an OGTT for screening. It is possible that especially
health-interested volunteers contacted us, and we therefore missed a
more vulnerable part of the population, which would then have
resulted in selection bias. However, this is also the case for most other
dietary or lifestyle intervention studies that recruit volunteers from
the general public.
The attrition rate was higher than estimated. We needed 1298
participants to complete the 3-year intervention and we achieved
962 (i.e. 74% of the target). Still, the incidence of T2D was similar in
the centres with higher (≥30%) versus lower attrition rates (<30%),
which suggests that the low incidence was indeed representative.
Undiagnosed cases among the drop-outs can be an issue. We
were, however, unable to approach drop-outs in all intervention cen-
tres, despite continued efforts, and therefore these data are not
available.
There was no beneficial effect of the HP, low GI diet, as we had
hypothesized. Indeed, the number of participants with nor-
moglycaemia was lower in this group. Therefore, it can be speculated
that an HP, low carbohydrate (even with low GI) combination or an
HP diet per se, may not be favourable in a population at risk of T2D.
The mechanisms are unclear. Some epidemiological studies support
that an HP diet may increase the risk of T2D30,31, while other studies
have observed a reduced risk of T2D.32 Adjusting for BMI or waist cir-
cumference often removed or reduced the associations. Also, the way
protein was expressed (e.g. g per day or g per kg of body weight daily)
greatly influenced the results.32 Because of the tight interplay of adi-
posity, insulin sensitivity and an individual's response to protein, it is
difficult to disentangle these components. However, an HP diet may
increase insulin demand, and this may raise the burden on insulin
secretion in vulnerable individuals, such as those with prediabetes.33
The recorded dietary intake showed significant differences in the
main targets, GI and protein content. However, differences were
smaller than planned. This corresponds to previous findings (e.g. the
DiOGenes study),10 and indicates that it is difficult to adhere to diets
with specific protein and GI targets. Compliance for protein intake,
assessed by urinary biomarkers, showed differences up to 52 weeks,
but MP had a mean protein intake of greater than 0.8 g/kg daily,
which may be sufficiently high to promote body weight mainte-
nance.34–38 Post hoc analyses showed a difference in 3-year weight-
loss maintenance between participants with a protein intake of <0.8
versus ≥0.8 g/kg daily, which confirmed a role of protein in weight-
loss maintenance. Adverse effects of a higher protein intake were not
observed or reported, although fewer participants achieved nor-
moglycaemia in HP than in MP at 3 years. Likewise, there were no
adverse effects on kidney function as assessed after 1 year in an
elderly group26 or in colon cancer risk markers assessed in a
subgroup.39
As for GI, the differences were also smaller than planned (4.7 to
3.3 units from week 26 to 156 compared with a goal of ≥6). But it is
more relevant to consider GL, which also takes total carbohydrate
intake into account. The differences between HP and MP that we
observed (16 to 13 units from week 26 to 156) apparently did not
affect our outcomes.
We did not see any differences in PA between the HI and MI
groups. The finding that fewer participants had normoglycaemia after
3 years in the HP-HI group compared with the other three groups
may, therefore, be solely by chance. Conversely, the differences in
normoglycaemia between HP and MP seemed robust throughout the
weight-maintenance phase.
The use of a specific behaviour modification tool (PREMIT) for
PREVIEW can be considered a strength.20 Thus, a higher visit atten-
dance was associated with greater weight-loss maintenance after
3 years. Further, PREVIEW used an LED for the first 8 weeks, which
resulted in a large, rapid weight loss (−11%). This degree of weight
loss appeared to be highly motivating for the participants as reflected
in higher intentions for healthy eating, PA and self-efficacy, and a
more positive perception about expected outcomes in those who had
achieved target weight loss compared with those who had not.40
The higher than expected attrition rate during the weight-
maintenance phase must be considered a weakness because it
decreased the statistical power for our primary outcome. The statisti-
cal power also decreased because of the very low number of T2D
cases, which (as stated above) was probably caused by the large initial
weight loss. The partial reversal of most improvements from 8 weeks
to the end is a concern, and it is possible that at 5 years there would
be no benefit concerning a reduction in T2D incidence. Unfortunately,
5-year data do not exist, but at 3 years the interventions were suc-
cessful compared with the predicted incidence.
In conclusion, 3-year incidence of T2D was lower than predicted
and did not differ between diets, PA or the four combined groups.
Maintaining the target intakes of protein and GI over 3 years
appeared difficult. However, the overall protocol was highly success-
ful in reducing the risk of conversion to T2D compared with esti-
mates from the literature, and the combination of rapid weight loss,
healthy eating and PA seemed to be effective in achieving this. As
far as clinically relevant outcomes are concerned, this is of great
importance.
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